Fact CheckerSign in

NCT05541783Completed

Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric Cancer

A Multi-center Prospective Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopic-assisted Distal Gastrectomy (LADG) and Totally Laparoscopic Distal Gastrectomy (TLDG) for Gastric Cancer

Source: ClinicalTrials.gov · Last updated 30 Jun 2026

Brief summary (registry, in English)

The aim of this study is comparing the short-term quality of life between laparoscopy-assisted distal gastrectomy and totally laparoscopic distal gastrectomy for gastric cancer.

Status (registry)
Completed
Study type
Interventional
Enrollment
213 (actual)
First submitted
6 Sept 2022
Start date
15 Sept 2022
Primary completion date
15 Jan 2025
Lead sponsor
Fudan University
NCT number
NCT05541783

What you commit to

  • Study type: Interventional
  • Participants enrolled: 213
  • From 15 Sept 2022 to the primary completion date, 15 Jan 2025
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients had history of chemotherapy, radiotherapy, immunotherapy or target therapy;
  • Patients had any concurrent or previous malignant tumor;
  • Patients had unstable cardiovascular, respiratory, kidney, or liver disease and poorly controlled hypertension, diabetes, mental disorders; history of upper abdominal surgery (except laparoscopic cholecystectomy).

Other

  • Patients had bulky regional lymph nodes (larger than 3 cm at the long diameter) or possible distant metastasis in preoperative evaluation
  • Patients were histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy).

Who the study is looking for

  • Aged 20-80 years;
  • Patients had an Eastern Cooperative Oncology Group performance status score of 0 or 1;
  • Patients had histologically confirmed gastric adenocarcinoma (tumor size\<5cm) at clinical stage I-III with T1-4aN0-2M0 excluding T4b or N3 tumors, according to the of the American Joint Committee on Cancer classification system, eighth edition;
  • Patients were expected to undergo laparoscopic distal gastrectomy with D2 lymphadenectomy.

Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fudan University Shanghai Cancer Center
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status
Changhai Hospital
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.